Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT05287126Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in ulcerative colitis (UC), sponsored by Pfizer. Primary endpoint: Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score at 52 weeks. Started Dec 2022; status: recruiting.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05287126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287126.